

# Sharon J Hutchinson

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/5694008/sharon-j-hutchinson-publications-by-citations.pdf>

**Version:** 2024-02-21

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

172  
papers

6,924  
citations

41  
h-index

79  
g-index

191  
ext. papers

8,319  
ext. citations

6.4  
avg, IF

5.68  
L-index

#	Paper	IF	Citations
172	Meta-analysis of drug-related deaths soon after release from prison. <i>Addiction</i> , <b>2010</b> , 105, 1545-54	4.6	410
171	Hepatitis C virus treatment for prevention among people who inject drugs: Modeling treatment scale-up in the age of direct-acting antivirals. <i>Hepatology</i> , <b>2013</b> , 58, 1598-609	11.2	366
170	Treatment of hepatitis C virus infection among people who are actively injecting drugs: a systematic review and meta-analysis. <i>Clinical Infectious Diseases</i> , <b>2013</b> , 57 Suppl 2, S80-9	11.6	248
169	The impact of needle and syringe provision and opiate substitution therapy on the incidence of hepatitis C virus in injecting drug users: pooling of UK evidence. <i>Addiction</i> , <b>2011</b> , 106, 1978-88	4.6	246
168	Combination interventions to prevent HCV transmission among people who inject drugs: modeling the impact of antiviral treatment, needle and syringe programs, and opiate substitution therapy. <i>Clinical Infectious Diseases</i> , <b>2013</b> , 57 Suppl 2, S39-45	11.6	228
167	Are needle and syringe programmes associated with a reduction in HIV transmission among people who inject drugs: a systematic review and meta-analysis. <i>International Journal of Epidemiology</i> , <b>2014</b> , 43, 235-48	7.8	224
166	Accelerating the elimination of viral hepatitis: a Lancet Gastroenterology & Hepatology Commission. <i>The Lancet Gastroenterology and Hepatology</i> , <b>2019</b> , 4, 135-184	18.8	216
165	Interventions to prevent HIV and Hepatitis C in people who inject drugs: a review of reviews to assess evidence of effectiveness. <i>International Journal of Drug Policy</i> , <b>2014</b> , 25, 34-52	5.5	196
164	Evidence for the effectiveness of sterile injecting equipment provision in preventing hepatitis C and human immunodeficiency virus transmission among injecting drug users: a review of reviews. <i>Addiction</i> , <b>2010</b> , 105, 844-59	4.6	189
163	Can antiviral therapy for hepatitis C reduce the prevalence of HCV among injecting drug user populations? A modeling analysis of its prevention utility. <i>Journal of Hepatology</i> , <b>2011</b> , 54, 1137-44	13.4	182
162	Needle and syringe programmes and opioid substitution therapy for preventing HCV transmission among people who inject drugs: findings from a Cochrane Review and meta-analysis. <i>Addiction</i> , <b>2018</b> , 113, 545-563	4.6	176
161	Male drugs-related deaths in the fortnight after release from prison: Scotland, 1996-99. <i>Addiction</i> , <b>2003</b> , 98, 185-90	4.6	175
160	Cost-effectiveness of hepatitis C virus antiviral treatment for injection drug user populations. <i>Hepatology</i> , <b>2012</b> , 55, 49-57	11.2	171
159	Hepatitis C virus infection epidemiology among people who inject drugs in Europe: a systematic review of data for scaling up treatment and prevention. <i>PLoS ONE</i> , <b>2014</b> , 9, e103345	3.7	160
158	Risk of hospital admission with coronavirus disease 2019 in healthcare workers and their households: nationwide linkage cohort study. <i>BMJ, The</i> , <b>2020</b> , 371, m3582	5.9	153
157	Influence of alcohol on the progression of hepatitis C virus infection: a meta-analysis. <i>Clinical Gastroenterology and Hepatology</i> , <b>2005</b> , 3, 1150-9	6.9	151
156	Prioritization of HCV treatment in the direct-acting antiviral era: An economic evaluation. <i>Journal of Hepatology</i> , <b>2016</b> , 65, 17-25	13.4	134

155	Risks of and risk factors for COVID-19 disease in people with diabetes: a cohort study of the total population of Scotland. <i>Lancet Diabetes and Endocrinology, the</i> , <b>2021</b> , 9, 82-93	18.1	112
154	Needle syringe programmes and opioid substitution therapy for preventing hepatitis C transmission in people who inject drugs. <i>The Cochrane Library</i> , <b>2017</b> , 9, CD012021	5.2	111
153	Modeling the current and future disease burden of hepatitis C among injection drug users in Scotland. <i>Hepatology</i> , <b>2005</b> , 42, 711-23	11.2	105
152	Incarceration history and risk of HIV and hepatitis C virus acquisition among people who inject drugs: a systematic review and meta-analysis. <i>Lancet Infectious Diseases, The</i> , <b>2018</b> , 18, 1397-1409	25.5	86
151	Toward a more complete understanding of the association between a hepatitis C sustained viral response and cause-specific outcomes. <i>Hepatology</i> , <b>2015</b> , 62, 355-64	11.2	83
150	Model projections on the impact of HCV treatment in the prevention of HCV transmission among people who inject drugs in Europe. <i>Journal of Hepatology</i> , <b>2018</b> , 68, 402-411	13.4	77
149	HCV treatment rates and sustained viral response among people who inject drugs in seven UK sites: real world results and modelling of treatment impact. <i>Journal of Viral Hepatitis</i> , <b>2015</b> , 22, 399-408	3.4	77
148	Rapid decline in HCV incidence among people who inject drugs associated with national scale-up in coverage of a combination of harm reduction interventions. <i>PLoS ONE</i> , <b>2014</b> , 9, e104515	3.7	66
147	Hepatitis C virus treatment as prevention in people who inject drugs: testing the evidence. <i>Current Opinion in Infectious Diseases</i> , <b>2015</b> , 28, 576-82	5.4	65
146	Modelling the impact of incarceration and prison-based hepatitis C virus (HCV) treatment on HCV transmission among people who inject drugs in Scotland. <i>Addiction</i> , <b>2017</b> , 112, 1302-1314	4.6	63
145	Cost-effectiveness of HCV case-finding for people who inject drugs via dried blood spot testing in specialist addiction services and prisons. <i>BMJ Open</i> , <b>2013</b> , 3,	3	63
144	The risk of hepatocellular carcinoma in cirrhotic patients with hepatitis C and sustained viral response: Role of the treatment regimen. <i>Journal of Hepatology</i> , <b>2018</b> , 68, 646-654	13.4	60
143	Detection of hepatitis C virus RNA in dried blood spots. <i>Journal of Clinical Virology</i> , <b>2012</b> , 54, 106-9	14.5	54
142	Rise in testing and diagnosis associated with Scotland@ Action Plan on Hepatitis C and introduction of dried blood spot testing. <i>Journal of Epidemiology and Community Health</i> , <b>2014</b> , 68, 1182-8	5.1	51
141	Mortality of those who attended drug services in Scotland 1996-2006: record-linkage study. <i>International Journal of Drug Policy</i> , <b>2012</b> , 23, 24-32	5.5	50
140	Is increased hepatitis C virus case-finding combined with current or 8-week to 12-week direct-acting antiviral therapy cost-effective in UK prisons? A prevention benefit analysis. <i>Hepatology</i> , <b>2016</b> , 63, 1796-808	11.2	49
139	Risk of transmission associated with sharing drug injecting paraphernalia: analysis of recent hepatitis C virus (HCV) infection using cross-sectional survey data. <i>Journal of Viral Hepatitis</i> , <b>2014</b> , 21, 25-32	3.4	48
138	Excess liver-related morbidity of chronic hepatitis C patients, who achieve a sustained viral response, and are discharged from care. <i>Hepatology</i> , <b>2011</b> , 54, 1547-58	11.2	48

137	Strategies for the treatment of Hepatitis C in an era of interferon-free therapies: what public health outcomes do we value most?. <i>Gut</i> , <b>2015</b> , 64, 1800-9	19.2	46
136	A record-linkage study of drug-related death and suicide after hospital discharge among drug-treatment clients in Scotland, 1996-2006. <i>Addiction</i> , <b>2013</b> , 108, 377-84	4.6	43
135	One-year follow-up of opiate injectors treated with oral methadone in a GP-centred programme. <i>Addiction</i> , <b>2000</b> , 95, 1055-68	4.6	43
134	Global progress on the elimination of viral hepatitis as a major public health threat: An analysis of WHO Member State responses 2017. <i>JHEP Reports</i> , <b>2019</b> , 1, 81-89	10.3	42
133	Quantifying the fraction of cirrhosis attributable to alcohol among chronic hepatitis C virus patients: implications for treatment cost-effectiveness. <i>Hepatology</i> , <b>2013</b> , 57, 451-60	11.2	42
132	The contribution of alcohol use disorder to decompensated cirrhosis among people with hepatitis C: An international study. <i>Journal of Hepatology</i> , <b>2018</b> , 68, 393-401	13.4	42
131	A population-based record linkage study of mortality in hepatitis C-diagnosed persons with or without HIV coinfection in Scotland. <i>Statistical Methods in Medical Research</i> , <b>2009</b> , 18, 271-83	2.3	41
130	aMAP risk score predicts hepatocellular carcinoma development in patients with chronic hepatitis. <i>Journal of Hepatology</i> , <b>2020</b> , 73, 1368-1378	13.4	41
129	Does informing people who inject drugs of their hepatitis C status influence their injecting behaviour? Analysis of the Networks II study. <i>International Journal of Drug Policy</i> , <b>2014</b> , 25, 179-82	5.5	39
128	Factors associated with injecting risk behaviour among serial community-wide samples of injecting drug users in Glasgow 1990-94: implications for control and prevention of blood-borne viruses. <i>Addiction</i> , <b>2000</b> , 95, 931-40	4.6	39
127	Mortality in hepatitis C patients who achieve a sustained viral response compared to the general population. <i>Journal of Hepatology</i> , <b>2017</b> , 66, 19-27	13.4	37
126	Association between harm reduction intervention uptake and recent hepatitis C infection among people who inject drugs attending sites that provide sterile injecting equipment in Scotland. <i>International Journal of Drug Policy</i> , <b>2012</b> , 23, 346-52	5.5	36
125	Rapid Epidemiological Analysis of Comorbidities and Treatments as risk factors for COVID-19 in Scotland (REACT-SCOT): A population-based case-control study. <i>PLoS Medicine</i> , <b>2020</b> , 17, e1003374	11.6	36
124	Hepatitis C reinfection following treatment induced viral clearance among people who have injected drugs. <i>Drug and Alcohol Dependence</i> , <b>2016</b> , 165, 53-60	4.9	36
123	A matched comparison study of hepatitis C treatment outcomes in the prison and community setting, and an analysis of the impact of prison release or transfer during therapy. <i>Journal of Viral Hepatitis</i> , <b>2016</b> , 23, 1009-1016	3.4	35
122	Drug-related deaths by region, sex, and age group per 100 injecting drug users in Scotland, 2000-01. <i>Lancet, The</i> , <b>2003</b> , 362, 941-4	4.0	35
121	Modelling the spread of hepatitis C virus infection among injecting drug users in Glasgow: Implications for prevention. <i>International Journal of Drug Policy</i> , <b>2006</b> , 17, 211-221	5.5	34
120	Re-emergence of HIV related to injecting drug use despite a comprehensive harm reduction environment: a cross-sectional analysis. <i>Lancet HIV, the</i> , <b>2019</b> , 6, e315-e324	7.8	32

119	Uptake of hepatitis C specialist services and treatment following diagnosis by dried blood spot in Scotland. <i>Journal of Clinical Virology</i> , <b>2014</b> , 61, 359-64	14.5	32
118	Modelling the prevalence of HCV amongst people who inject drugs: an investigation into the risks associated with injecting paraphernalia sharing. <i>Drug and Alcohol Dependence</i> , <b>2013</b> , 133, 172-9	4.9	32
117	Association of self-reported alcohol use and hospitalization for an alcohol-related cause in Scotland: a record-linkage study of 23,183 individuals. <i>Addiction</i> , <b>2009</b> , 104, 593-602	4.6	31
116	Trends in mortality after diagnosis of hepatitis C virus infection: an international comparison and implications for monitoring the population impact of treatment. <i>Journal of Hepatology</i> , <b>2015</b> , 62, 269-77	13.4	30
115	Targeted hepatitis C antibody testing interventions: a systematic review and meta-analysis. <i>European Journal of Epidemiology</i> , <b>2015</b> , 30, 115-29	12.1	27
114	Prior information in behavioral capture-recapture methods: demographic influences on drug injectors propensity to be listed in data sources and their drug-related mortality. <i>American Journal of Epidemiology</i> , <b>2005</b> , 162, 694-703	3.8	27
113	Engagement in a National Naloxone Programme among people who inject drugs. <i>Drug and Alcohol Dependence</i> , <b>2016</b> , 162, 236-40	4.9	26
112	Effectiveness of needle/syringe programmes and opiate substitution therapy in preventing HCV transmission among people who inject drugs. <i>Cochrane Database of Systematic Reviews</i> , <b>2016</b> , 2016,		26
111	Innovative strategies for the elimination of viral hepatitis at a national level: A country case series. <i>Liver International</i> , <b>2019</b> , 39, 1818-1836	7.9	25
110	Decrease in health-related quality of life associated with awareness of hepatitis C virus infection among people who inject drugs in Scotland. <i>Journal of Hepatology</i> , <b>2013</b> , 58, 460-6	13.4	25
109	Incomplete contingency tables with censored cells with application to estimating the number of people who inject drugs in Scotland. <i>Statistics in Medicine</i> , <b>2014</b> , 33, 1564-79	2.3	25
108	High response and re-infection rates among people who inject drugs treated for hepatitis C in a community needle and syringe programme. <i>Journal of Viral Hepatitis</i> , <b>2019</b> , 26, 519-528	3.4	25
107	Cost-Effectiveness of HBV and HCV Screening Strategies--A Systematic Review of Existing Modelling Techniques. <i>PLoS ONE</i> , <b>2015</b> , 10, e0145022	3.7	23
106	Estimating current injectors in Scotland and their drug-related death rate by sex, region and age-group via Bayesian capture--recapture methods. <i>Statistical Methods in Medical Research</i> , <b>2009</b> , 18, 341-59	2.3	23
105	Ranking predictors of a sustained viral response for patients with chronic hepatitis C treated with pegylated interferon and ribavirin in Scotland. <i>European Journal of Gastroenterology and Hepatology</i> , <b>2012</b> , 24, 646-55	2.2	23
104	Increased risk of HIV and other drug-related harms associated with injecting in public places: national bio-behavioural survey of people who inject drugs. <i>International Journal of Drug Policy</i> , <b>2020</b> , 77, 102663	5.5	23
103	The contribution of health risk behaviors to excess mortality in American adults with chronic hepatitis C: A population cohort-study. <i>Hepatology</i> , <b>2018</b> , 67, 97-107	11.2	23
102	Expansion of HCV treatment access to people who have injected drugs through effective translation of research into public health policy: Scotland experience. <i>International Journal of Drug Policy</i> , <b>2015</b> , 26, 1041-9	5.5	22

101	The provision of non-needle/syringe drug injecting paraphernalia in the primary prevention of HCV among IDU: a systematic review. <i>BMC Public Health</i> , <b>2010</b> , 10, 721	4.1	22
100	Drugs-Related Death Soon after Hospital-Discharge among Drug Treatment Clients in Scotland: Record Linkage, Validation, and Investigation of Risk-Factors. <i>PLoS ONE</i> , <b>2015</b> , 10, e0141073	3.7	22
99	Impact of current and scaled-up levels of hepatitis C prevention and treatment interventions for people who inject drugs in three UK settings-what is required to achieve the WHO HCV elimination targets?. <i>Addiction</i> , <b>2018</b> , 113, 1727	4.6	22
98	Estimating prevalence of injecting drug users and associated heroin-related death rates in England by using regional data and incorporating prior information. <i>Journal of the Royal Statistical Society Series A: Statistics in Society</i> , <b>2014</b> , 177, 209-236	2.1	21
97	Injecting drug users in Scotland, 2006: Listing, number, demography, and opiate-related death-rates. <i>Addiction Research and Theory</i> , <b>2013</b> , 21, 235-246	2.6	21
96	Staying hepatitis C negative: A systematic review and meta-analysis of cure and reinfection in people who inject drugs. <i>Liver International</i> , <b>2019</b> , 39, 2244-2260	7.9	20
95	Sudden rise in uptake of hepatitis B vaccination among injecting drug users associated with a universal vaccine programme in prisons. <i>Vaccine</i> , <b>2004</b> , 23, 210-4	4.1	20
94	Genome-Wide Association Study for Alcohol-Related Cirrhosis Identifies Risk Loci in MARC1 and HNRNPUL1. <i>Gastroenterology</i> , <b>2020</b> , 159, 1276-1289.e7	13.3	19
93	Review and meta-analysis of the association between self-reported sharing of needles/syringes and hepatitis C virus prevalence and incidence among people who inject drugs in Europe. <i>International Journal of Drug Policy</i> , <b>2013</b> , 24, 85-100	5.5	19
92	Association between harm reduction intervention uptake and skin and soft tissue infections among people who inject drugs. <i>Drug and Alcohol Dependence</i> , <b>2017</b> , 174, 91-97	4.9	18
91	Patient-important benefits of clearing the hepatitis C virus through treatment: a simulation model. <i>Journal of Hepatology</i> , <b>2014</b> , 60, 1118-26	13.4	18
90	Cohort Profile: The Hepatitis C Virus (HCV) Research UK Clinical Database and Biobank. <i>International Journal of Epidemiology</i> , <b>2017</b> , 46, 1391-1391h	7.8	17
89	Estimating the number of people with hepatitis C virus who have ever injected drugs and have yet to be diagnosed: an evidence synthesis approach for Scotland. <i>Addiction</i> , <b>2015</b> , 110, 1287-300	4.6	17
88	Prison-based prescriptions aid Scotland's National Naloxone Programme. <i>Lancet, The</i> , <b>2017</b> , 389, 1005-1006	10.6	16
87	Evaluating the cost-effectiveness of existing needle and syringe programmes in preventing hepatitis C transmission in people who inject drugs. <i>Addiction</i> , <b>2019</b> , 114, 560-570	4.6	16
86	Evaluating the population impact of hepatitis C direct acting antiviral treatment as prevention for people who inject drugs (EPIToPe) - a natural experiment (protocol). <i>BMJ Open</i> , <b>2019</b> , 9, e029538	3	16
85	Attendance at specialist hepatitis clinics and initiation of antiviral treatment among persons chronically infected with hepatitis C: examining the early impact of Scotland's Hepatitis C Action Plan. <i>Journal of Viral Hepatitis</i> , <b>2014</b> , 21, 366-76	3.4	16
84	Estimating the number of injecting drug users in Scotland's HCV-diagnosed population using capture-recapture methods. <i>Epidemiology and Infection</i> , <b>2014</b> , 142, 200-7	4.3	16

83	Global hepatitis C elimination: an investment framework. <i>The Lancet Gastroenterology and Hepatology</i> , <b>2020</b> , 5, 927-939	18.8	16
82	A hepatitis C avidity test for determining recent and past infections in both plasma and dried blood spots. <i>Journal of Clinical Virology</i> , <b>2013</b> , 57, 29-35	14.5	15
81	Assessing the impact and cost-effectiveness of needle and syringe provision and opioid substitution therapy on hepatitis C transmission among people who inject drugs in the UK: an analysis of pooled data sets and economic modelling. <i>Public Health Research</i> , <b>2017</b> , 5, 1-118	1.7	15
80	Trends in hepatocellular carcinoma incidence and survival among people with hepatitis C: An international study. <i>Journal of Viral Hepatitis</i> , <b>2018</b> , 25, 473-481	3.4	15
79	Association between universal hepatitis B prison vaccination, vaccine uptake and hepatitis B infection among people who inject drugs. <i>Addiction</i> , <b>2018</b> , 113, 80-90	4.6	14
78	Comparative effectiveness of antiviral treatment for hepatitis B: a systematic review and Bayesian network meta-analysis. <i>European Journal of Gastroenterology and Hepatology</i> , <b>2015</b> , 27, 882-94	2.2	14
77	Risk of Hepatitis C virus re-infection following spontaneous viral clearance in injecting drug users: a systematic review. <i>International Journal of Drug Policy</i> , <b>2011</b> , 22, 102-8	5.5	14
76	Real-world impact following initiation of interferon-free hepatitis C regimens on liver-related outcomes and all-cause mortality among patients with compensated cirrhosis. <i>Journal of Viral Hepatitis</i> , <b>2020</b> , 27, 270-280	3.4	14
75	Securing sustainable funding for viral hepatitis elimination plans. <i>Liver International</i> , <b>2020</b> , 40, 260-270	7.9	14
74	Evidence of continued injecting drug use after attaining sustained treatment-induced clearance of the hepatitis C virus: Implications for reinfection. <i>Drug and Alcohol Dependence</i> , <b>2015</b> , 154, 125-31	4.9	13
73	Mortality and cause of death in a cohort of people who had ever injected drugs in Glasgow: 1982-2012. <i>Drug and Alcohol Dependence</i> , <b>2015</b> , 147, 215-21	4.9	13
72	Hepatitis C prevalence in injecting drug users in Europe, 1990-2007: impact of study recruitment setting. <i>Epidemiology and Infection</i> , <b>2013</b> , 141, 563-72	4.3	13
71	Hospitalization of hepatitis C-diagnosed individuals in Scotland for decompensated cirrhosis: a population-based record-linkage study. <i>European Journal of Gastroenterology and Hepatology</i> , <b>2010</b> , 22, 49-57	2.2	13
70	Modelling the impact of a national scale-up of interventions on hepatitis C virus transmission among people who inject drugs in Scotland. <i>Addiction</i> , <b>2018</b> , 113, 2118-2131	4.6	13
69	Prognosis of 1169 hepatitis C chronically infected patients with decompensated cirrhosis in the predirect-acting antiviral era. <i>Journal of Viral Hepatitis</i> , <b>2017</b> , 24, 295-303	3.4	12
68	A time since onset of injection model for hepatitis C spread amongst injecting drug users. <i>Journal of Mathematical Biology</i> , <b>2013</b> , 66, 935-78	2	12
67	Global policy and access to new hepatitis C therapies for people who inject drugs. <i>International Journal of Drug Policy</i> , <b>2015</b> , 26, 1064-71	5.5	12
66	The EASL-Lancet Liver Commission: protecting the next generation of Europeans against liver disease complications and premature mortality. <i>Lancet, The</i> , <b>2021</b> ,	40	12

65	Liver mortality attributable to chronic hepatitis C virus infection in Denmark and Scotland--using spontaneous resolvers as the benchmark comparator. <i>Hepatology</i> , <b>2016</b> , 63, 1506-16	11.2	12
64	A global investment framework for the elimination of hepatitis B. <i>Journal of Hepatology</i> , <b>2021</b> , 74, 535-549	13.4	12
63	Among Cirrhotic Patients with a Hepatitis C Sustained Viral Response, the Risk of De-novo Hepatocellular Carcinoma Relates to Baseline Factors and Not the Use of Direct Acting Antivirals: Results from a Nationwide Cohort. <i>Journal of Hepatology</i> , <b>2017</b> , 66, S22-S23	13.4	11
62	Determinants of hepatitis C antiviral effectiveness awareness among people who inject drugs in the direct-acting antiviral era. <i>International Journal of Drug Policy</i> , <b>2018</b> , 52, 115-122	5.5	11
61	Trends in the incidence of HIV in Scotland, 1988-2009. <i>Sexually Transmitted Infections</i> , <b>2012</b> , 88, 194-9	2.8	11
60	The prevalence of hepatitis C virus among people of South Asian origin in Glasgow - results from a community based survey and laboratory surveillance. <i>Travel Medicine and Infectious Disease</i> , <b>2013</b> , 11, 301-9	8.4	10
59	Associations of severe COVID-19 with polypharmacy in the REACT-SCOT case-control study		10
58	Limited impact of awareness-raising campaigns on hepatitis C testing practices among general practitioners. <i>Journal of Viral Hepatitis</i> , <b>2017</b> , 24, 944-954	3.4	9
57	Impact of previous hepatitis B infection on the clinical outcomes from chronic hepatitis C? A population-level analysis. <i>Journal of Viral Hepatitis</i> , <b>2018</b> , 25, 930-938	3.4	9
56	The successful implementation of Scotland's Hepatitis C Action Plan: what can other European stakeholders learn from the experience? A Scottish voluntary sector perspective. <i>BMC Infectious Diseases</i> , <b>2014</b> , 14 Suppl 6, S7	4	9
55	Reduction in the population prevalence of hepatitis C virus viraemia among people who inject drugs associated with scale-up of direct-acting anti-viral therapy in community drug services: real-world data. <i>Addiction</i> , <b>2021</b> , 116, 2893-2907	4.6	9
54	Emergence of Novel Psychoactive Substance injecting associated with rapid rise in the population prevalence of hepatitis C virus. <i>International Journal of Drug Policy</i> , <b>2019</b> , 66, 30-37	5.5	8
53	What is the impact of a country-wide scale-up in antiviral therapy on the characteristics and sustained viral response rates of patients treated for hepatitis C?. <i>Journal of Hepatology</i> , <b>2015</b> , 62, 262-8	13.4	8
52	Population impact of direct-acting antiviral treatment on new presentations of hepatitis C-related decompensated cirrhosis: a national record-linkage study. <i>Gut</i> , <b>2020</b> , 69, 2223-2231	19.2	7
51	Inpatient hospital burden of hepatitis C-diagnosed patients with decompensated cirrhosis. <i>Liver International</i> , <b>2018</b> , 38, 1402-1410	7.9	7
50	Use of laboratory-based surveillance data to estimate the number of people chronically infected with hepatitis B living in Scotland. <i>Epidemiology and Infection</i> , <b>2014</b> , 142, 2121-30	4.3	7
49	Missing targets on drugs-related deaths, and a Scottish paradox. <i>International Journal of Drug Policy</i> , <b>2010</b> , 21, 155-9	5.5	7
48	Estimating the prevalence, incidence and cessation of injecting drug use in Glasgow 1960-2000: Combining expert opinion with capture-recapture prevalence data. <i>International Journal of Drug Policy</i> , <b>2006</b> , 17, 29-34	5.5	7



47	Sharing a household with children and risk of COVID-19: a study of over 300,000 adults living in healthcare worker households in Scotland		7
46	The Hep-CORE policy score: A European hepatitis C national policy implementation ranking based on patient organization data. <i>PLoS ONE</i> , <b>2020</b> , 15, e0235715	3.7	7
45	Do the most heavily burdened countries have the right policies to eliminate viral hepatitis B and C?. <i>The Lancet Gastroenterology and Hepatology</i> , <b>2020</b> , 5, 948-953	18.8	7
44	Matched population-based study examining the risk of type 2 diabetes in people with and without diagnosed hepatitis C virus infection. <i>Journal of Viral Hepatitis</i> , <b>2016</b> , 23, 596-605	3.4	7
43	The association between alcohol use and hepatitis C status among injecting drug users in Glasgow. <i>Drug and Alcohol Dependence</i> , <b>2012</b> , 123, 180-9	4.9	6
42	A record linkage study of hospital episodes for drug treatment clients in Scotland, 1996-2006. <i>Addiction Research and Theory</i> , <b>2013</b> , 21, 52-61	2.6	6
41	The Scottish Alcoholic Liver disease Evaluation: A Population-Level Matched Cohort Study of Hospital-Based Costs, 1991-2011. <i>PLoS ONE</i> , <b>2016</b> , 11, e0162980	3.7	6
40	Population-level effectiveness of a national HIV preexposure prophylaxis programme in MSM. <i>Aids</i> , <b>2021</b> , 35, 665-673	3.5	6
39	Reduction in the incidence of hepatitis C-related decompensated cirrhosis associated with national scale-up of direct-acting antiviral therapies targeting patients with advanced liver fibrosis. <i>Journal of Hepatology</i> , <b>2018</b> , 68, S67	13.4	6
38	Modeling the initiation of others into injection drug use, using data from 2,500 injectors surveyed in Scotland during 2008-2009. <i>American Journal of Epidemiology</i> , <b>2015</b> , 181, 771-80	3.8	5
37	HCV avidity as a tool for detection of recent HCV infection: Sensitivity depends on HCV genotype. <i>Journal of Medical Virology</i> , <b>2018</b> , 90, 120-130	19.7	5
36	P734 A SYSTEMATIC REVIEW OF INTERVENTIONS TO REDUCE ALCOHOL CONSUMPTION AMONG INDIVIDUALS WITH CHRONIC HCV INFECTION. <i>Journal of Hepatology</i> , <b>2014</b> , 60, S314-S315	13.4	5
35	Real-world utility of HCV core antigen as an alternative to HCV RNA testing: Implications for viral load and genotype. <i>Journal of Viral Hepatitis</i> , <b>2020</b> , 27, 996-1002	3.4	4
34	Uptake of endoscopic screening for gastroesophageal varices and factors associated with variceal bleeding in patients with chronic hepatitis C infection and compensated cirrhosis, 2005-2016: a national database linkage study. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2019</b> , 50, 425-434	6.1	3
33	Monitoring response to hepatitis B and C in EU/EEA: testing policies, availability of data on care cascade and chronic viral hepatitis-related mortality - results from two surveys (2016). <i>HIV Medicine</i> , <b>2018</b> , 19 Suppl 1, 11-15	2.7	3
32	Targets for Hepatitis C virus test uptake and case-finding among injecting drug users: In prisons and general practice. <i>Addiction Research and Theory</i> , <b>2010</b> , 18, 421-432	2.6	3
31	Population-level estimates of hepatitis C reinfection post scale-up of direct-acting antivirals among people who inject drugs. <i>Journal of Hepatology</i> , <b>2021</b> ,	13.4	3
30	Rapid Epidemiological Analysis of Comorbidities and Treatments as risk factors for COVID-19 in Scotland (REACT-SCOT): a population-based case-control study		3

29	Real-world outcomes of rapid regional hepatitis c virus treatment scale-up among people who inject drugs in Tayside, Scotland. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2021</b> ,	6.1	3
28	P1271 : How should scale up of HCV antiviral treatment be prioritized? A cost-effectiveness analysis including individual and population prevention benefits. <i>Journal of Hepatology</i> , <b>2015</b> , 62, S835	13.4	2
27	Spore forming bacteria infections and people who inject drugs: Implications for harm reduction. <i>International Journal of Drug Policy</i> , <b>2018</b> , 53, 45-54	5.5	2
26	Strategies to reduce HCV disease burden and HCV transmission need different models, as what works for end-stage liver disease may not work for HCV prevalence: a comment on the results presented in JVH Special Issue. <i>Journal of Viral Hepatitis</i> , <b>2014</b> , 21, e167-8	3.4	2
25	Examining the impact of the first wave of COVID-19 and associated control measures on interventions to prevent blood-borne viruses among people who inject drugs in Scotland: an interrupted time series study.. <i>Drug and Alcohol Dependence</i> , <b>2022</b> , 232, 109263	4.9	2
24	Perspectives on pre-exposure prophylaxis for people who inject drugs in the context of an hiv outbreak: A qualitative study. <i>International Journal of Drug Policy</i> , <b>2021</b> , 88, 103033	5.5	2
23	The prevalence and impact of thrombocytopenia, anaemia and leucopenia on sustained virological response in patients receiving hepatitis C therapy: evidence from a large real world cohort. <i>European Journal of Gastroenterology and Hepatology</i> , <b>2016</b> , 28, 398-404	2.2	1
22	The seroprevalence of hepatitis C virus infection among children and their mothers attending for dental care in Glasgow, Scotland, United Kingdom. <i>Journal of Infection and Public Health</i> , <b>2017</b> , 10, 470-478	7.4	1
21	Performance of models to predict hepatocellular carcinoma risk among UK patients with cirrhosis and cured HCV infection. <i>JHEP Reports</i> , <b>2021</b> , 3, 100384	10.3	1
20	The reported clear cut time association between interferon-free treatment and HCCQs anything but clear cut. <i>Journal of Hepatology</i> , <b>2020</b> , 72, 1034-1035	13.4	1
19	Relation of severe COVID-19 in Scotland to transmission-related factors and risk conditions eligible for shielding support: REACT-SCOT case-control study		1
18	Evaluation of the scale-up of HIV testing among people who inject drugs in Scotland in the context of an ongoing HIV outbreak. <i>International Journal of Drug Policy</i> , <b>2021</b> , 96, 103304	5.5	1
17	The impact of direct-acting antivirals on hepatitis C viraemia among people who inject drugs in England; real-world data 2011-2018. <i>Journal of Viral Hepatitis</i> , <b>2021</b> , 28, 1452-1463	3.4	1
16	Hepatitis C test uptake among historic blood transfusion recipients following media coverage of the Penrose Inquiry and an awareness-raising campaign. <i>Journal of Viral Hepatitis</i> , <b>2019</b> , 26, 93-100	3.4	1
15	High willingness to use drug consumption rooms among people who inject drugs in Scotland: findings from a national bio-behavioural survey among people who inject drugs. <i>International Journal of Drug Policy</i> , <b>2021</b> , 90, 102731	5.5	1
14	The uptake of foil from needle and syringe provision services and its role in smoking or snorting heroin among people who inject drugs in Scotland. <i>International Journal of Drug Policy</i> , <b>2021</b> , 98, 103369	5.5	0
13	Reply. <i>Hepatology</i> , <b>2018</b> , 67, 1173	11.2	
12	Competing Risk Bias in Prognostic Models Predicting Hepatocellular Carcinoma Occurrence: Impact on Clinical Decision-making <b>2022</b> , 1, 129-136		

- 11 Uptake of interferon-free DAA therapy among HCV-infected decompensated cirrhosis patients and evidence for decreased mortality. *Journal of Viral Hepatitis*, **2021**, 28, 1246-1255 3.4
- 10 PTH-104 Hospital Admissions and Associated Costs of Alcoholic Liver Disease in Scotland Between 1991 and 2011. *Gut*, **2016**, 65, A270.1-A270 19.2
- 9 Rapid Epidemiological Analysis of Comorbidities and Treatments as risk factors for COVID-19 in Scotland (REACT-SCOT): A population-based case-control study **2020**, 17, e1003374
- 8 Rapid Epidemiological Analysis of Comorbidities and Treatments as risk factors for COVID-19 in Scotland (REACT-SCOT): A population-based case-control study **2020**, 17, e1003374
- 7 Rapid Epidemiological Analysis of Comorbidities and Treatments as risk factors for COVID-19 in Scotland (REACT-SCOT): A population-based case-control study **2020**, 17, e1003374
- 6 Rapid Epidemiological Analysis of Comorbidities and Treatments as risk factors for COVID-19 in Scotland (REACT-SCOT): A population-based case-control study **2020**, 17, e1003374
- 5 Rapid Epidemiological Analysis of Comorbidities and Treatments as risk factors for COVID-19 in Scotland (REACT-SCOT): A population-based case-control study **2020**, 17, e1003374
- 4 The Hep-CORE policy score: A European hepatitis C national policy implementation ranking based on patient organization data **2020**, 15, e0235715
- 3 The Hep-CORE policy score: A European hepatitis C national policy implementation ranking based on patient organization data **2020**, 15, e0235715
- 2 The Hep-CORE policy score: A European hepatitis C national policy implementation ranking based on patient organization data **2020**, 15, e0235715
- 1 The Hep-CORE policy score: A European hepatitis C national policy implementation ranking based on patient organization data **2020**, 15, e0235715